Keele Research Repository

Article

Oswald, AJ, Symeonides, SN, Wheatley, D, Chan, S, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, McAdam, K, Schmid, P, Waters, S, Poole, C, Twelves, C, Perren, T, Bartlett, J, Piper, T, Chisholm, EM, Welsh, M, Hill, R, Hopcroft, LEM, Barrett-Lee, P and Cameron, DA (2023) Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment.

Glynn, D, Bliss, J, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Coles, CE, Wheatley, D, Haviland, JS, Kirby, AM, Longo, F, Faria, R, Yarnold, JR and Griffin, S (2022) Cost-effectiveness of 5 fraction and partial breast radiotherapy for early breast cancer in the UK: model-based multi-trial analysis. Breast Cancer Research and Treatment. 1 - 12.

Wheatley, D, Haviland, J, Patel, J, Sydenham, M, Alhasso, A, Chan, C, Cleator, S, Coles, C, Donovan, E, Kirby, A, Kirwan, C, Nabi, Z, Sawyer, E, Somaiah, N, Syndikus, I, Venables, K, Yarnold, J, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 and Bliss, J (2022) First results of FAST-Forward phase 3 RCT nodal substudy: 3-year normal tissue effects. Radiotherapy and Oncology, 170. S75 - S76.

Brunt, AM, Haviland, JS, Sydenham, M, Agrawal, RK, Algurafi, H, Alhasso, A, Barrett-Lee, P, Bliss, P, Bloomfield, D, Bowen, J, Donovan, E, Goodman, A, Harnett, A, Hogg, M, Kumar, S, Passant, H, Quigley, M, Sherwin, L, Stewart, A, Syndikus, I, Tremlett, J, Tsang, Y, Venables, K, Wheatley, D, Bliss, JM and Yarnold, JR (2020) Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. Journal of Clinical Oncology, 38 (28). pp. 3261-3272.

Schmid, P, Abraham, J, Chan, S, Wheatley, D, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Nemsadze, G, Baird, RD, Park, YH, Hall, PS, Perren, T, Stein, RC, Mangel, L, Ferrero, J-M, Phillips, M, Conibear, J, Cortes, J, Foxley, A, de Bruin, EC, McEwen, R, Stetson, D, Dougherty, B, Sarker, S-J, Prendergast, A, McLaughlin-Callan, M, Burgess, M, Lawrence, C, Cartwright, H, Mousa, K and Turner, NC (2020) Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38 (5). 423 - 433.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Algurafi, H, Alhasso, A, Bliss, P, Bloomfield, D, Emson, M, Goodman, A, Harnett, A, Passant, H, Tsang, YM, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). International Journal of Radiation Oncology*Biology*Physics, 102 (5). 1603 -1604.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Alhasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Rada, Z, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. British Journal of Cancer, 119 (11). 41 - 41.

Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Haviland, J, Sydenham, M, Al-hasso, A, Bloomfield, D, Chan, C, Churn, M, Cleator, S, Coles, C, Emson, M, Goodman, A, Griffin, C, Harnett, A, Hopwood, P, Kirby, A, Kirwan, C, Morris, C, Sawyer, E, Somaiah, N, Syndikus, I, Wilcox, M, Zotova, R, Wheatley, D, Bliss, J and Yarnold, J (2018) FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy: 3-year normal tissue effects. Radiotherapy and Oncology, 127 (S1). S311 -S312.

Megias, D, Sydenham, M, Wheatley, D, Maclennan, M, Spezi, E and Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097 (2017) Evaluating variability of contouring using ESTRO guidelines for elective breast cancer radiotherapy. Radiotherapy and Oncology, 123. S136 - S137.

Coles, C, Griffin, C, Kirby, A, Agrawal, R, Alhasso, A, Bhattacharya, I, Brunt, AM ORCID: https://orcid.org/0000-0002-4797-5097, Ciurlionis, L, Chan, H, Donovan, E, Emson, M, Harnett, A, Haviland, J, Hopwood, P, Jefford, M, Kaggwa, R, Sawyer, E, Sybdikus, I, Tsang, Y, Wheatley, D, Wilcox, M, Yarnold, J and Bliss, J (2017) Partial breast radiotherapy after breast conservation: 5 year outcomes from the IMPORT LOW (CRUK/06/003) phase III trial. Radiotherapy and Oncology, 123 (S1). S162 -S163.

Brunt, AM, Wheatley, D, Yarnold, J, Somaiah, N, Kelly, S, Harnett, A, Coles, C, Goodman, A, Bahl, A, Churn, M, Zotova, R, Sydenham, M, Griffin, CL, Morden, JP and Bliss, JM (2016) Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120 (1). pp. 114-118.

Conference or Workshop Item

Schmid, P, Abraham, J, Chan, S, Wheatley, D, Brunt, M ORCID: https://orcid.org/0000-0002-4797-5097, Nemsadze, G, Baird, R, Park, YH, Hall, P, Perren, T, Stein, RC, Laszlo, M, Ferrero, J-M, Phillips, M, Conibear, J, Sarker, S-J, Prendergast, A, Cartwrightx, H, Mousa, K and Turner, NC (2018) AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial. In: 2018 ASCO Annual Meeting I, 01-05 Jun 2018.